Meng Xiangjun, Yao Jiayi, Gu Jingkai
School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Research Center for Drug Metabolism, School of Life Sciences, Jilin University, Changchun, 130012, China.
J Pharm Anal. 2025 Jan;15(1):101070. doi: 10.1016/j.jpha.2024.101070. Epub 2024 Aug 14.
Significant investment in nanocarrier drug delivery systems (Nano-DDSs) has yielded only a limited number of successfully marketed nanomedicines, highlighting a low rate of clinical translation. A primary contributing factor is the lack of foundational understanding of processes. Comprehensive knowledge of the pharmacokinetics of Nano-DDSs is essential for developing more efficacious nanomedicines and accurately evaluating their safety and associated risks. However, the complexity of Nano-DDSs has impeded thorough and systematic pharmacokinetic studies. Key components of pharmacokinetic investigations on Nano-DDSs include the analysis of the released drug, the encapsulated drug, and the nanomaterial, which present a higher level of complexity compared to traditional small-molecule drugs. Establishing an appropriate approach for monitoring the pharmacokinetics of Nano-DDSs is crucial for facilitating the clinical translation of nanomedicines. This review provides an overview of advanced bioanalytical methodologies employed in studying the pharmacokinetics of anticancer organic Nano-DDSs over the past five years. We hope that this review will enhance the understanding of the pharmacokinetics of Nano-DDSs and support the advancement of nanomedicines.
对纳米载体药物递送系统(Nano-DDSs)的大量投资仅产生了数量有限的成功上市的纳米药物,这凸显了临床转化的低成功率。一个主要的促成因素是对相关过程缺乏基本的了解。全面了解Nano-DDSs的药代动力学对于开发更有效的纳米药物以及准确评估其安全性和相关风险至关重要。然而,Nano-DDSs的复杂性阻碍了全面而系统的药代动力学研究。Nano-DDSs药代动力学研究的关键组成部分包括对释放的药物、包封的药物和纳米材料的分析,与传统小分子药物相比,这些分析呈现出更高的复杂性。建立一种合适的方法来监测Nano-DDSs的药代动力学对于促进纳米药物的临床转化至关重要。本综述概述了过去五年用于研究抗癌有机Nano-DDSs药代动力学的先进生物分析方法。我们希望本综述将增进对Nano-DDSs药代动力学的理解,并支持纳米药物的发展。